Anti-Mici antibody also available as a subcutaneous injection

New subcutaneous formulation for vedolizumab monoclonal antibody, biotechnological drug with intestinal selectivity, already available in intravenous formulation for the treatment of adult patients with moderate to severe ulcerative colitis or active Crohn’s disease. There new method of administration in syringe or pre-filled pen, recently authorized by the Italian drug agency Aifa, represents “a turning point – Takeda announces – for all patients who were used to having to go to the hospital of reference for the infusion”, and who will now be able to “receive treatment directly at home or in a doctor’s office“, or also “self-administer the drug after adequate training by the reference specialist “.